India, Oct. 20 -- Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, presented new clinical and translational findings for its investigational drug PALI-2108 at UEG Week 2026 in Barcelona, Spain. The findings highlighted early improvements in intestinal inflammation and endoscopic disease activity in patients with inflammatory bowel disease.
PALI-2108 is an oral, once-daily PDE4 inhibitor prodrug designed to activate in the terminal ileum and colon. Its active metabolite, PALI-0008, inhibits PDE4, increasing intracellular cyclic adenosine monophosphate (cAMP) to help regulate inflammatory signaling.
In a Phase 1b open-label study involving five patients with fibros...